中文版 English
News > YHLO News
Chinese Vaccine Development Has Entered Clinical Trials
According to CCTV news reports, in the evening of the 16th March, the recombinant COVID-19 vaccine developed by Academician Chen Wei's team was approved to start a clinical trial. On the same day, The New York Times published the news that the National Institute of Allergy and Infectious Diseases (NIAID) co-developed the COVID-19 vaccines also started clinical trials.       

An expert mentioned, “We have been vaccinated against measles and diphtheria when we were young. We hope that this vaccine can produce corresponding antibodies in our bodies. But the characteristics of each virus are different. For example, we have to get influenza vaccine every year, while the measles vaccination only one time. By now, although we have some understanding of the characteristics of SARA-CoV-2, the understanding of it is just beginning. Even if COVID-9 vaccine is developed, it’s hard to tell how long the immunity will last.”

The expert told reporters that the development of the COVID-9 vaccine is a very difficult task. "For coronavirus, no vaccine is currently commercialized, that means there is no successful vaccine for human-infected coronaviruses. Although serval countries have started R&D, it’s only the first step, there is still a long way to go. "

Safety first: Regulations and technical requirements must be consistent with international standards such as WHO
Vaccine development takes a relatively long time, and one of the main reasons is to ensure the safety of the vaccine. Academician Chen Wei said in an interview that according to international standards and domestic regulations, vaccines have been prepared in advance for safe, effective, controllable quality and mass production. 

China's Strength
Under the premise of safety, some people are also concerned about "who will develop the vaccine first". In this regard, China is not behind the United States. Chinese private companies might not be strong in vaccine R&D, but Chinese national organizations had more R&D power in this field, which can accelerate the R&D process in vaccine development.

The SARS-CoV-2 virus first attach to the host cell by binding to the cell surface receptor, such as ACE2, through the RBD part of the S protein. Then fusion peptide enters into the host cell membrane and become part of host cell, releasing the nucleic acid molecules into the cell to complete infection process. YHLO’s SARS-CoV-2 IgM/IgG kits can detect antibodies against S protein. It can be used to support diagnosis of confirmed patients and vaccine development process. It can be used to monitor the effectiveness of the vaccine.

CopyRight@2019 Shenzhen YHLO Biotech Co., Ltd. rights reserved
Headquarter: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
Int'l Business Office: Rm.501, Building A1, Kexing Science Park, No.15 Keyuan Road, Nanshan District, 518057 Shenzhen, P.R.China
Tel: +86 755 26601910   /   Fax: +86 755 26473319   /   Email: marketing@szyhlo.com

About YHLONewsProductsServicesJoin UsInvestor RelationsContact Us